A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

Key Points

Key points are not available for this paper at this time.

Abstract

Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic option.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Katharina A Mayer

Eva Schrezenmeier

Matthias Diebold

University of Basel

Journals

New England Journal of Medicine

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study